La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Arch Biopartners Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Richard Muruve

Amministratore delegato

CA$150.0k

Compenso totale

Percentuale dello stipendio del CEO	100.0%
Mandato del CEO	15yrs
Proprietà del CEO	15.0%
Durata media del management	12.9yrs
Durata media del Consiglio di amministrazione	14.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Richard Muruve rispetto agli utili di Arch Biopartners?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	n/a	n/a	-CA$2m
Dec 31 2023	n/a	n/a	-CA$2m
Sep 30 2023	CA$150k	CA$150k	-CA$3m
Jun 30 2023	n/a	n/a	-CA$4m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	n/a	n/a	-CA$3m
Sep 30 2022	CA$113k	CA$113k	-CA$1m
Jun 30 2022	n/a	n/a	-CA$257k
Mar 31 2022	n/a	n/a	-CA$423k
Dec 31 2021	n/a	n/a	CA$308k
Sep 30 2021	CA$100k	CA$100k	-CA$1m
Jun 30 2021	n/a	n/a	-CA$3m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	n/a	n/a	-CA$6m
Sep 30 2020	CA$383k	CA$100k	-CA$5m
Jun 30 2020	n/a	n/a	-CA$4m
Mar 31 2020	n/a	n/a	-CA$2m
Dec 31 2019	n/a	n/a	-CA$2m
Sep 30 2019	CA$100k	CA$100k	-CA$2m
Jun 30 2019	n/a	n/a	-CA$2m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	n/a	n/a	-CA$3m
Sep 30 2018	CA$100k	CA$100k	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$2m
Dec 31 2017	n/a	n/a	-CA$2m
Sep 30 2017	CA$100k	CA$100k	-CA$2m

Compensazione vs Mercato: La retribuzione totale di Richard ($USD 110.43K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 679.79K ).

Compensazione vs guadagni: La retribuzione di Richard è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Richard Muruve (53 yo)

15yrs

Mandato

CA$150,000

Compensazione

Mr. Richard Gabriel Muruve is a Co-Founder of Arch Biopartners Inc. and has been its Chief Executive Officer since August 2009 and President since May 12, 2010. Mr. Muruve served as Acting Chief Financial...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Muruve	Co-Founder	15yrs	CA$150.00k	15.03% CA$ 10.4m
Daniel Muruve	Co-Founder	12.9yrs	CA$289.00k	3.17% CA$ 2.2m
Andrew Bishop	CFO & Director	no data	CA$289.00k	1.21% CA$ 834.6k
Justin MacDonald	Co-Founder & Principal Scientist	no data	Nessun dato	Nessun dato
Paul Beck	Co-Founder & Principal Scientist	no data	Nessun dato	Nessun dato
Aaron Benson	Director of Communications	1.1yrs	Nessun dato	Nessun dato

12.9yrs

Durata media

Gestione esperta: Il team dirigenziale di ACHF.F è esperto e expertise (durata media dell'incarico 12.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Muruve	Co-Founder	19yrs	CA$150.00k	15.03% CA$ 10.4m
Daniel Muruve	Co-Founder	no data	CA$289.00k	3.17% CA$ 2.2m
Andrew Bishop	CFO & Director	14.3yrs	CA$289.00k	1.21% CA$ 834.6k
Claude Allary	Independent Director	10.3yrs	CA$289.00k	0.32% CA$ 221.5k
Richard Rossman	Independent Director	14.3yrs	Nessun dato	3.31% CA$ 2.3m
Robert Hodges	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Hindrik Mulder	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

14.3yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ACHF.F è composto da personale esperto e esperto (durata media dell'incarico 14.3 anni).

Arch Biopartners Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Recent updates

Arch Biopartners Inc. Announces its Cilastatin Drug Candidate to Participate in Pontiac Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.6 million in funding

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media